Drugs / ORAL-LYO-FMT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06948461 | Sep 2025 → Sep 2026 overdue | Clostridium difficile colitis, irritable bowel syndrome | PharmaPlanter Technologies Inc | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORAL-LYO-FMT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06948461 ↗ |
| Action | Restore | “The product aims to restore healthy gut microbiota” NCT06948461 ↗ |
| Route | Oral | “Participants receive 7 capsules, three times per week (Monday, Wednesday, Friday), for either 4 or 7 weeks depending on treatment allocation.” NCT06948461 ↗ |